

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

MYLAN PHARMACEUTICALS INC. and  
AMNEAL PHARMACEUTICALS LLC,

Petitioners

v.

YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Patent Owner

---

Case No. IPR2015-00643 (8,232,250 B2)  
Case No. IPR2015-00644 (8,399,413 B2)  
Case No. IPR2015-00830 (8,969,302 B2)<sup>1,2</sup>

---

**REQUEST FOR ORAL ARGUMENT**

---

<sup>1</sup> Case Nos. IPR2015-01976, IPR2015-01980 and IPR2015-01981 have been joined with these proceedings.

<sup>2</sup> An identical Request is being filed in each proceeding.

Pursuant to the Board's Scheduling Orders<sup>3</sup> and the Stipulation Regarding Due Dates Nos. 2, 4 and 5<sup>4</sup>, Petitioners Mylan Pharmaceuticals Inc. and Amneal Pharmaceuticals LLC. (collectively, "Petitioners") respectfully request oral argument, currently scheduled for May 12, 2016.

Pursuant to 37 C.F.R. § 42.70(a), Petitioners intend to argue the following issues:

1. Any issues addressed by Petitioners, including in the Petition for *Inter Partes Review* and Reply in any of the proceedings, including whether any claim of U.S. Patent No. 8,232,250; U.S. Patent No. 8,399,413; and/or U.S. Patent No. 8,969,302 are patentable.
2. Any issues properly raised by Patent Owner, including in Patent Owner's Responses.
3. Rebuttal to issues raised by Patent Owner.
4. Petitioners' motions to exclude evidence.
5. Any motions to exclude evidence by Patent Owner.
6. Any issues properly raised in Patent Owner's Request for Oral Argument.

---

<sup>3</sup> IPR2015-00643, Paper 14; IPR2015-00644, Paper 15, IPR2015-00830, Paper 9.

<sup>4</sup> IPR2015-00643, Paper 50; IPR2015-00644, Paper 51, IPR2015-00830, Paper 45.

Petitioners request that oral argument in IPR2015-00643, IPR2105-00644 and IPR2015-00830 be combined into a single argument, with each side having 60 minutes for oral argument. Petitioners also request the ability to use audio/visual equipment to display demonstrative exhibits, including the use of a projector and screen for a PowerPoint presentation. Because of the number of anticipated attendees at the hearing, Petitioners request that the largest hearing room available be reserved for the hearing.

Dated: April 13, 2016

/Brandon M. White/  
Brandon M. White Reg. No. 52,354  
PERKINS COIE LLP  
700 13th Street, NW, Suite 600  
Washington, D.C. 20005  
Telephone: (202) 654-6204  
Facsimile: (202) 654-6211  
Email: [bmwhite@perkinscoie.com](mailto:bmwhite@perkinscoie.com)  
*Attorney for Mylan Pharmaceuticals Inc.*

**CERTIFICATE OF SERVICE**

The undersigned hereby certifies that the foregoing Request for Oral Argument was served electronically via email as follows:

Patent Owners:

Elizabeth Holland  
Goodwin Procter LLP  
eholland@goodwinprocter.com

Nicholas Mitrokostas  
Goodwin Procter LLP  
nmitrokostas@goodwinprocter.com

William James  
Goodwin Procter LLP  
wjames@goodwinprocter.com

Daryl Wiesen  
Goodwin Procter LLP  
dwiesen@goodwinprocter.com

Eleanor Yost  
Goodwin Procter LLP  
eyost@goodwinprocter.com

John Bennett  
Goodwin Procter LLP  
jbennett@goodwinprocter.com

Petitioner Amneal Pharmaceuticals, LLC:

Vincent L. Capuano  
Duane Morris LLC  
VCapuano@duanemorris.com

Christopher S. Kroon  
Duane Morris LLC  
CSKroon@duanemorris.com

Dated: April 13, 2016

/Brandon M. White/\_\_\_\_\_.  
Brandon M. White

*Attorney for Mylan Pharmaceuticals Inc.*